After the Human Research Ethics Committee (HREC) rejected the Company’s flagship drug, EmtinB, knocking back years of research in the…
Clinical stage biopharmaceutical company Paradigm Biopharmaceuticals (ASX: PAR) has been given the green light to go ahead with a Phase…
Clinical data trials being conducted by Paradigm Biopharmaceuticals (ASX: PAR) continue to deliver impressive patient outcomes for sufferers of chronic…